tew-7197
Small moleculeexperimental
Clinical trial activity
8 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2014 (NCT02160106)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Healthy Volunteers · Phase 1
- Multiple Myeloma · Phase 1
- Myelodysplastic Syndromes · Phase 1/Phase 2
- Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1/Phase 2
- Stomach Neoplasms · Phase 1/Phase 2
Mechanism of action
SMAD3 inhibitor
SMAD2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- tew-7197
- tew-7197
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03732274 | Phase 1/Phase 2 (Phase 2) | Dec 15, 2018 | AstraZeneca, MedPacto, Inc. |
| NCT03724851 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2018 | MedPacto, Inc., Merck |
| NCT03666832 | Phase 1/Phase 2 (Phase 2) | Sep 17, 2018 | Sungkyunkwan University |
| NCT03698825 | Phase 1 | Aug 20, 2018 | MedPacto, Inc. |
| NCT03704675 | Phase 1 | Jul 25, 2018 | MedPacto, Inc. |
| NCT03143985 | Phase 1 | Jul 1, 2017 | Case Western Reserve University |
| NCT03074006 | Phase 1/Phase 2 (Phase 2) | Apr 3, 2017 | MedPacto, Inc. |
| NCT02160106 | Phase 1 | Jun 1, 2014 | MedPacto, Inc., National OncoVenture |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MedPacto, Inc. | For profit | 6 | 6 | 2 | 2014 |
| AstraZeneca | For profit | 1 | 0 | 1 | 2018 |
| Case Western Reserve University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Merck | For profit | 1 | 0 | 1 | 2018 |
| National OncoVenture | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Sungkyunkwan University | Academic/Hospital | 1 | 1 | 1 | 2018 |
6 organizations
Page 1 / 1